Customized Medicine Market place – Advances in Human Genomics and Proteomics to Challenge Classic Therapeutics — Marketplace Study Report

tags

Summary

GBI Investigation, the top company intelligence provider, has released its latest report, “Personalized Medicine Market place – Advances in Human Genomics and Proteomics to Challenge Standard Therapeutics” that offers key data, information and evaluation of the major trends and issues in Customized Medicine Industry. The report gives a comprehensive insight into the role of Human Genomics and Proteomics to challenge conventional therapeutics. The report also provides a detailed evaluation of industry characterization of personalized medicine industry in terms of its marketplace size, segmentation by essential geography varieties and the key market place drivers and barriers. The report also talks about the patent landscape for human genomics and proteomics and gives complete evaluation.

Scope

The scope of the report includes:
– Detailed overview of Personalized Medicine Market in pharmaceutical business along with their use, efficiency and limitation.
– Annualized industry information from 2007 and forecast forward till 2016 along with segmentation by geography.
– Essential industry drivers and restraints shaping the Personalized Medicine Market place.
– Competitive landscape evaluation with competitive profiling of major organizations.
– Evaluation of partnership deals from 2006 to 2010
– Analysis of M&ampA deals from 2005 to 2010 along with segmentation by value geography and firms.

Motives to acquire

The report will boost your choice generating capability. It will enable you to
– Develop better methods for personalized medicine market place research by understanding the industry dynamics.
– Create market-entry and industry expansion techniques by identifying the essential development area
– Understand the factors shaping the Personalized Medicine Market place
– For understanding the function of Human Genomics and Proteomics to challenge conventional therapeutics.
– Determine the important players ideal positioned to take the benefit of the opportunities in the global market place.
– Exploit partnership and acquisition possibilities by identifying the goods that could fill the portfolio gaps.

Table of Contents :

1 Table of Contents four
1.1 List of Tables 7
1.two List of Figures 9
two Personalized Medicine Marketplace: Market Overview 10
2.1 Introduction 10
2.1.1 Possible Applications of Personalized Medicine 12
two.2 GBI Investigation Report Guidance 14
3 Personalized Medicine Marketplace: Drivers and Barriers 15
three.1 Drivers 16
3.1.1 Increase in healthcare charges 16
3.1.two Positive aspects over conventional drug discovery strategies 16
3.1.3 Patient compliance 16
3.1.four Early detection of illness 17
3.1.5 Far better regulatory norms and validation procedures encourage development of the personalized medicine marketplace 17
three.2 Barriers 17
3.2.1 Payer Reimbursement Concerns 17
3.2.2 Ethical Issues 17
three.2.3 Health-related Information Technologies 18
3.2.four Awareness Gap – Lack of Doctor Education and Awareness about Novel Technologies 18
3.two.5 Cumbersome and Lengthy Improvement Procedure Discourages Biomarker Study by the Pharmaceutical Sector 18
four Personalized Medicine Market – Personalized Therapeutics and Diagnostics 19
4.1 Personalized Therapeutics – Drug Profiles 19
four.1.1 Herceptin (trastuzumab) 19
four.1.2 Erbitux (cetuximab) 24
4.1.3 Gleevec (imatinib) 28
four.1.four Zyprexa (olazapine) 32
four.1.5 Lipitor (atorvastatin) 35
4.1.six Celebrex (celecoxib) 39
4.1.7 Tarceva (erlotinib) 42
4.1.eight Rituxan (rituximab) 46
4.1.9 Plavix (clopidogrel bisulfate) 49
four.1.ten Risperdal (risperidone) 51
4.1.11 Vectibix (Panitumumab) 54
4.1.12 Coumadin (Warfarin) 56
4.1.13 Iressa (Gefitinib) 57
4.1.14 Sprycel 59
4.1.15 Camptosar 61
4.2 Companion Diagnostics 62
four.2.1 Chosen Companion Diagnostics Employed in Customized Healthcare 64
4.three Biomarkers 67
4.three.1 Biomarkers in Cancer Analysis 68
four.3.2 Marketplace Size and Forecasts 69
4.three.3 Segmentation by Indication 70
five Customized Medicine Market: Selected Pipeline Solution Profiles 80
five.1 PF-4948568 (Pfizer) 80
five.1.1 Overview 80
5.1.two Mechanism of Action 80
5.1.3 Clinical Study Specifics 80
five.two PF-02341066 + Erlotinib (Pfizer) 81
5.two.1 Overview 81
5.two.two Mechanism of Action 81
5.2.3 Clinical study particulars 81
five.3 PF-299804 (Pfizer) 82
5.3.1 Overview 82
5.3.2 Mechanism of action 82
five.three.three Clinical study specifics 82
5.four CEP-701 (Cephalon Inc.) 83
five.4.1 Overview 83
5.four.2 Mechanism of action 83
five.4.three Clinical study details 84
5.5 TBR-652 (Tobira Therapeutics, Inc) 84
5.five.1 Overview 84
five.five.2 Mechanism of action 84
5.5.3 Clinical study information 85
five.six Brivanib (Bristol-Myers Squibb) 85
5.6.1 Overview 85
five.six.two Mechanism of action 85
5.6.three Clinical study particulars 86
5.7 Ipilimumab (Bristol-Myers Squibb) 86
five.7.1 Overview 86
five.7.two Mechanism of Action 86
5.7.three Clinical Study Specifics 86
5.eight BiovaxID (Accentia Biopharmaceuticals, Inc.) 87
five.eight.1 Overview 87
five.eight.two Mechanism of Action 87
five.8.3 Clinical Study Information 87

For more info, please visit :
http://www.aarkstore.com/reports/Personalized-Medicine-Industry-Advances-in-Human-Genomics-and-Proteomics-to-Challenge-Conventional-Therapeutics-79681.html